🇺🇸 FDA
Pipeline program

Aglatimagene besadenovec

PaTK02

Phase 2 mab active

Quick answer

Aglatimagene besadenovec for Borderline Resectable Pancreatic Adenocarcinoma is a Phase 2 program (mab) at Candel Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Candel Therapeutics
Indication
Borderline Resectable Pancreatic Adenocarcinoma
Phase
Phase 2
Modality
mab
Status
active

Clinical trials